Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial

Overview of attention for article published in Nature Medicine, March 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 36 news outlets
blogs: 3 blogs
twitter: 40 X users
facebook: 1 Facebook page

wikipedia: 1 Wikipedia page
video: 1 YouTube creator
bluesky: 5 Bluesky users

Readers on

mendeley: 95 Mendeley

So far, Altmetric has seen 7 Bluesky posts from 5 Bluesky users, with an upper bound of 11,136 followers.

Laromestrocel therapy showed safety and slowed cognitive decline and brain atrophy in mild Alzheimer's disease patients. by Rash BG, Ramdas KN (...) Hare JM et 21 al. in Nat Med #MedSky 📖 read the article:

These results pave the way for larger clinical trials to explore the potential of stem cell therapy in AD. Exciting times ahead! 🧬✨ #AlzheimersResearch #StemCellTherapy #Neurodegeneration www.nature.com/articles/s41...

🧠 Key findings at 39 weeks: ✅ Slowed brain volume loss by 48.4% 🏥 ✅ Reduced hippocampal atrophy by 61.9% ✅ Improved cognitive & daily living assessments ✅ Decreased neuroinflammation

🔬✨ Promising new research in Alzheimer’s disease! A phase 2a trial tested the safety & efficacy of laromestrocel, a bone marrow-derived mesenchymal stem cell therapy, in slowing AD progression. The study met its primary safety endpoint with no serious…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 3 additional Bluesky posts.